Lonza, InduPro Enter Licensing Agreement for Next-Gen ADCs

Editor’s take: Alliance will leverage complementary technologies to develop therapeutic approaches that aim to address precision targeting and efficacy in oncology.

Lonza and InduPro, a biotechnology company developing next-generation therapeutics through the targeted proximity of cell-surface proteins, entered a licensing agreement to support the development of antibody-drug conjugate (ADC) therapies.

Under the agreement, Lonza, through one of its affiliated companies, will grant InduPro a non-exclusive, worldwide license to its GlycoConnect, HydraSpace and linker-payload technologies. These technologies will be applied to the development of antibody-drug conjugates (ADCs) targeting up to two oncology antigens, supporting the development of highly targeted cancer therapies.

InduPro will combine its bispecific antibody capabilities with Lonza’s ADC platform, including GlycoConnect, HydraSpace, and SYNtecan E. Leveraging these technologies, the companies aim to develop differentiated therapeutic approaches designed to address complex diseases such as cancer, where precision targeting and efficacy remain critically important.

Jan Vertommen, Vice President of Commercial Development, Advanced Synthesis, Lonza, commented: “We are pleased to be starting this collaboration with InduPro, which underscores the strength and versatility of our ADC platform. By combining our expertise in bioconjugation technologies and manufacturing with InduPro’s innovative proximity guided antibody platform, we reinforce our commitment to enabling our licensing partners and supporting the advancement of next-generation ADC programs.”

Prakash Raman, CEO of InduPro, added: “This agreement represents an important step in advancing our pipeline of proximity-driven bispecific ADCs. By combining InduPro’s ability to identify novel, disease-specific co-target pairs with Lonza’s industry-leading ADC technologies, we aim to develop differentiated, first-in-class therapeutics that improve selectivity, expand therapeutic windows, and ultimately deliver better outcomes for patients with hard-to-treat tumors.”